Results 241 to 250 of about 69,960 (284)
Some of the next articles are maybe not open access.
Therapeutic Drug Monitoring, 1983
The aminoglycoside antibiotics gentamicin and tobramycin have been monitored traditionally by measuring peak and trough drug levels in serum. We found interpretation of these data to be hazardous, due to variations in the drug administration-specimen collection process and routine medical events and practices.
J E, Gorsky, J R, Latts
openaire +2 more sources
The aminoglycoside antibiotics gentamicin and tobramycin have been monitored traditionally by measuring peak and trough drug levels in serum. We found interpretation of these data to be hazardous, due to variations in the drug administration-specimen collection process and routine medical events and practices.
J E, Gorsky, J R, Latts
openaire +2 more sources
American Journal of Otolaryngology, 1986
The author participated in two prospective studies of patients receiving aminoglycoside antibiotics. In the first study, 54 patients received amikacin, and 54 received gentamicin. In the second study, 61 patients received gentamicin, 50 received netilmicin, and 52 received tobramycin.
openaire +2 more sources
The author participated in two prospective studies of patients receiving aminoglycoside antibiotics. In the first study, 54 patients received amikacin, and 54 received gentamicin. In the second study, 61 patients received gentamicin, 50 received netilmicin, and 52 received tobramycin.
openaire +2 more sources
Aminoglycoside Vestibulotoxicity
2019Many pharmaceuticals have ototoxicity (both cochlear and/or vestibular) as part of their adverse medication profile. The aminoglycoside class of antimicrobials has been especially well studied in this regard. Many questions remain unanswered as to how to best monitor and prevent this complication.
openaire +2 more sources
Journal of Antimicrobial Chemotherapy, 1985
P, Noone, H G, Prentice, R J, Sage
openaire +2 more sources
P, Noone, H G, Prentice, R J, Sage
openaire +2 more sources
Aminoglycosides for the Treatment of Severe Infection Due to Resistant Gram-Negative Pathogens
Antibiotics, 2023Etienne de Montmollin +2 more
exaly